Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain

A Phase III, Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS® Hydromorphone HCl (NMED-1077) Compared to Placebo in Patients With Chronic Low Back Pain

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00549042

Enrollment

459

Registered

2007-10-25

Start date

2007-10-31

Completion date

2009-01-31

Last updated

2020-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Low Back Pain

Keywords

Back Pain, Chronic Low Back Pain, Chronic Back Pain, Pain, Chronic Pain

Brief summary

This study will test an experimental drug called OROS® hydromorphone hydrochloride (HCl) (NMED-1077), a once daily opioid analgesic that can relieve pain. A large number of clinical studies have been conducted to test this drug. OROS hydromorphone HCl is currently approved in both the US and Europe to treat chronic pain. The purpose of this study is to compare OROS hydromorphone to placebo to see if it is safe and efficacious.

Interventions

DRUGOROS hydromorphone

hydromorphone 12, 16, 24, 32, 40, 48, or 64 mg tablets

DRUGPlacebo

Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Patients must have been provided with written consent to participate in the study prior to any study procedures, and must understand that they are free to withdraw from the study at any time. 2. Patients who can speak, read, write, and understand English, and must be able to read and understand the consent form, complete study-related procedures, and communicate with the study staff. 3. Male and female patients aged 18-75 years, inclusive. 4. Documented diagnosis of moderate to severe chronic low back pain that must have been present 5. Patients who are classified as non-neuropathic (Class 1 and 2) or neuropathic (Class 3, 4, 5 and 6) of lower back pain based on the Quebec Task Force Classification of Spinal Disorders will be enrolled for this study. 6. Patients who require daily scheduled opioid analgesics for low back pain for at least 2 months prior to the screening visit. 7. Patients with a daily opioid requirement of ≥ 60 mg oral morphine equivalent (≥ 12 mg hydromorphone), but ≤ 320 mg morphine (≤ 64 mg hydromorphone) per day within the 2 months prior to the screening visit. 8. Patients who, in the Investigator's opinion, are on a stable dose (≥ 2 weeks) of all prior analgesics (both opioid and non-opioid) prior to the screening visit. 9. Female subjects of childbearing potential including those who have had a tubal ligation surgery but excluding those who have not experienced a menstrual period for a minimum of 2 years, must have a negative serum pregnancy test at screening visit, and must consent to utilize a medically acceptable method of contraception throughout the entire study period including the washout period and for 1 week after the study is completed.

Exclusion criteria

1. Patients with an active diagnosis of fibromyalgia, complex regional pain syndrome (including reflex sympathetic dystrophy or causalgia), acute spinal cord compression, severe or progressive lower extremity weakness or numbness, bowel or bladder dysfunction as a result of cauda equina compression, diabetic amyotrophy, meningitis, diskitis, back pain because of secondary infection or tumor, or pain caused by a confirmed or suspected neoplasm. 2. Patients who have undergone a surgical procedure for back pain within 6 months prior to the screening visit. 3. Patients who have had nerve or plexus block, including epidural steroid injections or facet blocks, within 1 month prior to the screening visit. 4. Patients with any other chronic pain condition that, in the investigator's opinion, would interfere with the assessment of low back pain (e.g., osteoarthritis, rheumatoid arthritis, postherpetic neuralgia, pain associated with diabetic neuropathy, migraine headaches requiring opioid therapy). 5. Patients who are involved in an active workman's compensation or insurance claim or disability claim or litigation related to back pain. 6. Patients who have by history used any illicit drugs of abuse, abused opioids or exhibited drug seeking behavior within 5 years prior to the screening visit. 7. Patients who have abused prescription medication or alcohol within 5 years prior to the screening visit. 8. Patients with a positive alcohol or drugs of abuse test 9. Women who are pregnant (as indicated by a positive result in a serum pregnancy test administered at screening visit), or breast feeding, or planning to breast feed within 30 days prior to the screening visit. 10. Patients who have demonstrated allergic reactions or hypersensitivity to opioids. 11. Patients who have had no bowel movement within three days, or bowel obstruction within 60 days, prior to the screening visit. 12. Patients with pre-existing severe narrowing of the gastrointestinal tract secondary to: prior gastrointestinal surgery (e.g., vagotomy, antrectomy, pyloroplasty, gastroplasty, gastrojejunostomy) or gastrointestinal disease resulting in impaired gastrointestinal function (e.g., paralytic ileus, gastroparesis, inflammatory bowel disease, short gut syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudoobstruction, or Meckel diverticulum) 13. Patients who have a major psychiatric condition (e.g., schizophrenia, major depression) or who have clinically significant anxiety or depression as defined by a Hospital Anxiety and Depression Scale(HADS) score greater than 10. 14. Patients who have received monoamine oxidase (MAO) inhibitors within 14 days prior to the screening visit. 15. Patients with clinically significant abnormal laboratory results in clinical chemistry, hematology or urinalysis including serum glutamic-oxaloacetic transaminase/aspartate aminotransferase (AST) or serum glutamic-pyruvic transaminase/alanine aminotransferase (ALT) ≥ 3.0 times the upper limit of the reference range or a serum creatinine ≥ 2.0 mg/dL at screening. 16. Patients with a serious or unstable intercurrent illness. 17. Patients with a history of uncontrolled seizure disorder. 18. Patients with increased intracranial pressure, mental clouding of unknown etiology, coma, or hypotension. 19. Patients who have severe asthma, severe chronic obstructive pulmonary disease, or any other disorder that predisposes the patient to carbon dioxide retention or respiratory depression. 20. Patients who have taken any investigational drug within 30 days prior to the screening visit or are currently enrolled in another investigational drug study.

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline to Week 12 in Mean Pain Intensity	Baseline, Week 12 (or final visit)	Participants rate their pain intensity on a numeric rating scale (NRS), where 0=no pain and 10=worst possible pain, in a daily diary. At Week 12 (or final visit), all measurements during the preceding week are averaged, and the mean change from the mean score at baseline is calculated.

Other

Measure	Time frame	Description
Change From Baseline in Mean Pain Intensity Scores Through the Entire 12-week Treatment Phase	Baseline through Week 12	Participants rate their pain on the pain intensity NRS in a daily diary. At each scheduled visit all measurements during the preceding week are collected, and a mean score for each arm is calculated for each visit. Mean scores at baseline and each subsequent visit are plotted on a graph for the entire 12-week treatment period, and an area under the curve calculation is used to determine the mean change from baseline for each arm through the entire 12-week treatment phase.
Change From Baseline in Mean Patient Global Assessment (PGA) Scores	Baseline through Week 12	Change from Baseline in mean PGA scores collected at each visit (at Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12) using the scale: 1=Excellent, 2=Very Good, 3=Good, 4=Fair, and 5=Poor. The worst possible score is 5.0.
Change From Baseline in Mean Scores on the Roland-Morris Disability Questionnaire	Baseline through Week 12	Change from baseline in the Roland-Morris Disability Questionnaire (RDQ) score was analyzed for each visit at which the RDQ was administered (Days 1, 8, and Weeks 2, 3, 4, 6, 8, 10, and 12). This is a 24-item inventory with scores ranging from 0 (highest ability) to 24 (lowest ability). Higher scores mean more disability.
Change From Baseline in Mean Pain Intensity Scores Collected at Scheduled Visits to the Clinic	Baseline through Week 12	Participants rate their pain on the pain intensity NRS at each scheduled visit (Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12), and a mean score is calculated.
Time to Treatment Failure	within 12 weeks	Time to treatment failure is the median number of days from baseline until the earliest day on which the patient's data indicated treatment failure.

Participant flow

Participants by arm

Arm	Count
OROS Hydromorphone OROS hydromorphone tablets administered orally once daily in total daily doses of 12, 16, 24, 32, 40, 48, or 64 mg	134
Placebo Matching placebo tablets orally once daily (number and dosage of tablets to match the number and dosage of the stable dose of OROS hydromorphone obtained in the Conversion and Titration phase).	134
Total	268

Baseline characteristics

Characteristic	Placebo	OROS Hydromorphone	Total
Age, Categorical <=18 years	0 Participants	0 Participants	0 Participants
Age, Categorical >=65 years	11 Participants	5 Participants	16 Participants
Age, Categorical Between 18 and 65 years	123 Participants	129 Participants	252 Participants
Age, Continuous	49.5 years STANDARD_DEVIATION 10.55	47.7 years STANDARD_DEVIATION 10.51	48.6 years STANDARD_DEVIATION 10.55
Region of Enrollment United States	134 Participants	134 Participants	268 Participants
Sex: Female, Male Female	73 Participants	61 Participants	134 Participants
Sex: Female, Male Male	61 Participants	73 Participants	134 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —
other Total, other adverse events	247 / 447	64 / 134	73 / 134
serious Total, serious adverse events	5 / 447	6 / 134	4 / 134

Outcome results

Primary

Change From Baseline to Week 12 in Mean Pain Intensity

Participants rate their pain intensity on a numeric rating scale (NRS), where 0=no pain and 10=worst possible pain, in a daily diary. At Week 12 (or final visit), all measurements during the preceding week are averaged, and the mean change from the mean score at baseline is calculated.

Time frame: Baseline, Week 12 (or final visit)

Population: Intent-to-treat population (ITT). One patient (randomized to receive OROS hydromorphone) did not report taking any study medication, and another (randomized to receive placebo) did not have Baseline values for the primary efficacy variable; both were excluded from the ITT population. Therefore, the ITT population had 266 patients.

Arm	Measure	Value (MEAN)
OROS Hydromorphone	Change From Baseline to Week 12 in Mean Pain Intensity	0.6 score on a scale
Placebo	Change From Baseline to Week 12 in Mean Pain Intensity	1.7 score on a scale

Other Pre-specified

Change From Baseline in Mean Pain Intensity Scores Collected at Scheduled Visits to the Clinic

Participants rate their pain on the pain intensity NRS at each scheduled visit (Baseline, Days 1, 4, 8, 11, and Weeks 2, 3, 4, 6, 8, 10, and 12), and a mean score is calculated.

Time frame: Baseline through Week 12